Wall Street Zen upgraded shares of Sunshine Biopharma (NASDAQ:SBFM – Free Report) to a hold rating in a report released on Saturday morning,Wall Street Zen reports.
Separately, Weiss Ratings upgraded Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 28th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.
Get Our Latest Stock Analysis on SBFM
Sunshine Biopharma Trading Down 6.1%
Shares of SBFM opened at $2.75 on Friday. The firm’s 50-day moving average is $13.75 and its two-hundred day moving average is $108.13. Sunshine Biopharma has a twelve month low of $2.58 and a twelve month high of $464.00. The firm has a market capitalization of $605,000.00, a P/E ratio of -0.01 and a beta of 1.20.
Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($23.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($24.00) by $1.00. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. The company had revenue of $9.26 million during the quarter, compared to analysts’ expectations of $8.70 million. Analysts predict that Sunshine Biopharma will post -39.00 EPS for the current year.
About Sunshine Biopharma
Sunshine Biopharma, Inc is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.
In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.
Further Reading
- Five stocks we like better than Sunshine Biopharma
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
